

Supplementary Materials

Table S1.

Days post infection	Virus type	Virus-Host Phenotype			
		Null	Chromosome-associated	Chromosome-associated / Telomere-integrated	Telomere-integrated only
1	Md5	4.5 ± 1.5	52.8 ± 4.0	31.5 ± 5.0	11.2 ± 3.5
1	Rispens	22.9 ± 4.7	53.2 ± 6.7	14.7 ± 4.0	9.2 ± 1.2
1	HVT	9.1 ± 2.1	54.6 ± 10.5	35.7 ± 8.5	0.7 ± 0.6
4	Md5	12.9 ± 1.7	40.5 ± 6.4	42.2 ± 13.7	4.3 ± 2.1
4	Rispens	12.2 ± 4.0	51.8 ± 15.1	36.0 ± 2.1	0.0 ± 0.0
4	HVT	17.7 ± 2.3	51.2 ± 9.2	31.1 ± 6.0	0.0 ± 0.0
7	Md5	14.6 ± 1.7	55.2 ± 3.1	26.1 ± 4.5	4.2** ± 1.5
7	Rispens	26.3* ± 1.7	51.9 ± 6.1	21.9 ± 7.0	0.0 ± 0.0
7	HVT	18.3 ± 1.5	76.3*† ± 7.0	5.3*‡ ± 1.0	0.0 ± 0.0
14	Md5	28.3 ± 10.0	23.1 ± 2.3	33.5 ± 16.6	15.0* ± 10.7
14	Rispens	36.1 ± 3.6	39.9 ± 8.2	23.4 ± 5.1	0.6 ± 0.6
14	HVT	24.9 ± 9.3	37.0 ± 4.0	37.6 ± 15.3	0.6 ± 0.6
21	Md5	18.8 ± 2.5	16.7** ± 3.2	29.7 ± 8.1	34.7** ± 2.0
21	Rispens	22.0 ± 5.0	55.9 ± 7.6	21.2 ± 2.1	0.9 ± 0.6
21	HVT	1.4** ± 1.2	58.6 ± 5.5	39.3 ± 3.1	0.7 ± 0.6

Supplementary Table 1. Viral-host cytogenomic interactions for oncogenic and non-oncogenic MDV strains in disease-resistant, genotype 6₃, chickens. The mean percentages, in bold font, ± standard deviation of mitotically-dividing cells with given virus-host phenotypes from 3 samples per treatment type (Md5; oncogenic MDV, non-oncogenic MD vaccines; Rispens, HVT) between 24 hours and 21 days post-infection. The samples represent the replicating cell population in the spleens of individual genotype 6₃ (MD-resistant) birds. The values that were statistically-significant within a

viral phenotype and within a timepoint as compared to the other treatment types (MDV strains) are indicated with a "*" ($p \leq 0.05$) or "***" ($p \leq 0.01$) symbol. The values that were found to be statistically-significant within a virus-host phenotype for a treatment type (MDV strain) across timepoints are indicated with a "†" ($p \leq 0.05$) or "‡" ($p \leq 0.01$) symbol.